We initiate coverage on TINC with an Outperform recommendation and a target price of € 13.0/sh. With investments focused on securing long-term cashflows, we see TINC generating cash far in excess of distributions in future, enabling distribution growth at a CAGR of ~4% in our forecast period. We also forecast the portfolio fair value (FV) expanding strongly (CAGR +9.4% 2024-34), largely on the back of unrealised gains, as the company is expected to expand its sector agnostic investments in the S...
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participat...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
WDP's FY25 results were fully in line but the company surprised in already revealing its 2030 targets. We like such long-term visibility combined with very clear targets: €500m of yearly capex that can be auto-financed, delivering a +6% CAGR. WDP now has pan-European ambitions and aims to establish a presence in Italy and Spain. While the company has not delivered on its entrance into Germany, we think that opening itself to new countries is the right ambition to have at this stage. The plan loo...
Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 5, 6, and 9, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 2, 2026, followed by its controlle...
Galapagos ontvangt transparantieverklaringen van Bank of America Mechelen, België; 10 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 5, 6 en 9 februari 2026 transparantieverklaringen van Bank of America Corporation. Daaruit blijkt dat Bank of America Corporation, als controlerende entiteit, op 2 februari 2026 de drempel van 5% van de stemrechten van Galapagos heeft overschreden, gevolgd door haar gecontro...
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Syensqo - Participation notification by BlackRock Inc. Communiqué de pressePersbericht Regulated Participation notification by BlackRock Inc. Brussels, Belgium – February 04, 2026 - 08:30 CET According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (12 Throgmorton Avenue, London EC2N 2DL, UK) recently sent Syensqo the following transparency notifications indicating that it crossed the threshold of 3%. Here is the summary of the moves: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transaction...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.